Brii Biosciences Publishes Positive Phase II Results for HBV Treatment
China’s Brii Biosciences (HKG: 2137) has announced the publication of interim results from a Phase...
RNAi / ASO
Junshi Biosciences’ JS401 Accepted for Review by China’s NMPA for Hyperlipidemia
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that the National Medical Products Administration...
Sirnaomics Accelerates STP705 Development After Positive Skin Cancer Trial Results
Sirnaomics Ltd (HKG: 2257) is advancing the clinical development of STP705 following positive results from...
Sirnaomics’ Lead Candidate STP707 Shows Promising Phase I Data
Sino-US small interfering RNA (siRNA) specialist Sirnaomics (HKG: 2257) has revealed that its lead pipeline...
ChainGen Bio Raises RMB 45M in Angel Round for X-oligo Conjugates Development
ChainGen Bio, a Shanghai-based developer of X-oligo conjugates (XOCs), has reportedly raised RMB 45 million...
Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development
Ausper Biopharma, Inc, a developer of drugs and vaccines for chronic hepatitis B virus (HBV)...
Sciwind Biosciences Partners with SynerK for siRNA Therapeutics Development
Hangzhou Sciwind Biosciences Co., Ltd has announced a research partnership with SynerK Inc. The collaboration...
Sirnaomics Initiates Phase I Study of STP705 for Abdominal Fat Reduction
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the first subject dosing in...
Sirnaomics’ STP705 Achieves 100% Complete Remission in Basal Cell Carcinoma Study
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced positive results from a Phase II...
Sirnaomics’ STP705 Receives Approval for Liver Cancer Trial in Taiwan
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced that it has received approval from...
Sirnaomics’ STP705 Shows Promising Results in Skin Cancer Trial
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced the peer-reviewed publication of Phase IIa...